MapLight GC sells 13,917 shares in planned trades

MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported open-market sales of 13,917 shares of Voting Common Stock on May 11, 2026 under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported open-market sales of 13,917 shares of Voting Common Stock on May 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. The trades were executed in four tranches at weighted average prices between $27.61 and $30.56 per share.

After these transactions, Hanson directly holds 162,331 shares of MapLight Therapeutics. The filing notes that each reported price is a weighted average of multiple trades within disclosed price ranges, and Hanson has agreed to provide detailed breakdowns of individual sale prices upon request.

Insights

Insider trading analyst

Pre-planned insider share sales represent a modest, routine disposition.

Kristopher Hanson, General Counsel of MapLight Therapeutics, sold 13,917 shares of Voting Common Stock in four open-market transactions. All trades occurred on May 11, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating the timing was scheduled in advance.

The reported sale prices are weighted averages, with underlying trades executed in ranges from $27.26 to $30.90 per share. Following the sales, Hanson continues to hold 175,964 shares directly, and the filing shows no remaining derivative positions such as options or warrants.

Because the transactions are plan-based and Hanson retains a substantial equity position, they typically carry limited informational value about management’s current outlook. Future company filings may provide additional context on any further pre-planned trades or changes in insider holdings.

Insider Trade Summary 10b5-1

Net Seller: 13,917 shares

Net Sell 4 txns

Insider Hanson Kristopher

Role General Counsel

Sold 13,917 shs ($419K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	284	$27.61	$8K
Sale	Voting Common Stock	846	$28.70	$24K
Sale	Voting Common Stock	6,979	$30.04	$210K
Sale	Voting Common Stock	5,808	$30.56	$177K

Holdings After Transaction: Voting Common Stock — 162,331 shares (Direct)

Footnotes (5)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.2965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 13,917 shares Price tranche 1: $27.61 per share Price tranche 2: $28.70 per share +4 more

7 metrics

Shares sold 13,917 shares Total Voting Common Stock sold on May 11, 2026

Price tranche 1 $27.61 per share Open-market sale weighted average price

Price tranche 2 $28.70 per share Open-market sale weighted average price

Price tranche 3 $30.04 per share Open-market sale weighted average price

Price tranche 4 $30.56 per share Open-market sale weighted average price

Post-sale holdings 175,964 shares Direct Voting Common Stock held after final transaction

Sale transactions 4 transactions Number of open-market sale entries reported

Key Terms

Rule 10b5-1 trading plan, weighted average price, Voting Common Stock, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Voting Common Stock financial

"security_title: "Voting Common Stock""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MapLight Therapeutics (MPLT) shares did Kristopher Hanson sell?

Kristopher Hanson sold 13,917 shares of MapLight Therapeutics Voting Common Stock. The Form 4 shows four open-market sale transactions totaling 13,917 shares on May 11, 2026, at weighted average prices between $27.61 and $30.56 per share.

What role does Kristopher Hanson hold at MapLight Therapeutics (MPLT)?

Kristopher Hanson is the General Counsel of MapLight Therapeutics. The Form 4 identifies him as an officer with the title General Counsel, making his transactions reportable as insider trades under SEC rules for company officers.

Were Kristopher Hanson’s MPLT share sales made under a Rule 10b5-1 plan?

Yes, the sales were executed under a Rule 10b5-1 trading plan. A footnote states the transactions were made pursuant to a trading plan adopted on December 29, 2025, indicating the sale timing was scheduled in advance rather than decided spontaneously.

What prices did Kristopher Hanson receive for his MPLT share sales?

The reported sale prices ranged from $27.61 to $30.56 per share. Each Form 4 line uses a weighted average price, with detailed footnotes describing underlying trade ranges between $27.26 and $30.90 per share across multiple transactions.

How many MapLight Therapeutics (MPLT) shares does Kristopher Hanson hold after the sales?

After the reported transactions, Hanson directly holds 175,964 MPLT shares. Each transaction line lists post-trade holdings, and the final entry shows a direct ownership position of 175,964 shares of Voting Common Stock following the May 11, 2026 sales.

Did the Form 4 report any option exercises or derivative transactions for MPLT?

No, the filing reports only common stock sale transactions. The transaction records are all non-derivative Voting Common Stock sales, and the derivative position summary is empty, indicating no reported option exercises, conversions, or other derivative events in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanson Kristopher

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	05/11/2026		S(1)		284	D	$27.61(2)	175,964	D
Voting Common Stock	05/11/2026		S(1)		846	D	$28.7(3)	175,118	D
Voting Common Stock	05/11/2026		S(1)		6,979	D	$30.04(4)	168,139	D
Voting Common Stock	05/11/2026		S(1)		5,808	D	$30.56(5)	162,331	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.2965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)